|Home | About | Journals | Submit | Contact Us | Français|
The scaffolding PDZ-domain containing protein MDA-9/syntenin is a tandem PDZ protein overexpressed in human melanoma, and breast and gastric cancer cells. MDA-9/syntenin affects cancer cell motility and invasion through distinct biochemical and signaling pathways, including focal adhesion kinase (FAK) and p38 mitogen-activated protein kinase (MAPK), resulting in activation of the NFκ B pathway. MDA9/syntenin also promotes melanoma metastasis by activating c-Src, but how c-Src regulates NFκ B activation is unclear. Using a human melanoma model, we document that MDA-9/syntenin/c-Src interactions are positive regulators of NFκ B activation. Inhibition of c-Src by PP2 treatment, by blocking c-Src or mda-9/syntenin expression with siRNA, or in c-Src (−/−) knockout cell lines, reduces NFκ B activation following overexpression of mda-9/syntenin or c-Src. Deletion or point mutations of the PDZ binding motif preventing MDA-9/syntenin association with c-Src reveals that both PDZ domains, with PDZ2 being the dominant module, are required for activating downstream signaling pathways, including p38 MAPK and NFκ B. We also document that MDA-9/syntenin/c-Src complexes functionally cooperate with NFκ B to promote anchorage-independent growth, motility and invasion of melanoma cells. These findings underscore PDZ domains of MDA-9/syntenin as promising potential therapeutic targets for intervening in a decisive component of cancer progression, namely metastatic tumor spread.
Melanoma differentiation associated gene-9 (MDA-9), also called syntenin, is an important member of an expanding family of scaffolding PDZ domain-containing proteins first identified by subtraction hybridization as a novel gene differentially expressed in human melanoma cells reprogrammed to terminally differenciate (Lin et al., 1996; 1998). However, rather than exhibiting a monophasic induction profile, mda-9/syntenin displays biphasic expression consisting of an early enhancement followed by decreased expression during the course of reversion of the cancer phenotype in human melanoma cells to a more normal state (Lin et al., 1996; 1998) suggesting a potential role in melanoma development and progression. Consistent with the above findings, recent data from our laboratory (Boukerche et al., 2005) and others (Koo et al., 2002; Helmke et al., 2004) implicate MDA-9/syntenin in the pathogenesis and progression of multiple cancers, including breast, gastric, and melanoma. Using a clinically relevant melanoma model, we recently validated mda-9/syntenin as an important metastasis-associated gene that promotes tumor cell dissemination in vivo (Boukerche et al., 2005).
MDA-9/syntenin possesses two evolutionarily conserved postsynaptic density-95/disks large/zonula occludens-1 (PDZ) domains of 83- and 80-amino-acid residues, respectively (PDZ1 and PDZ2) (Schultz et al., 2000), that play a central role in signaling pathways by organizing networks of receptors and in targeting selected cellular proteins to multiprotein complexes (Sarkar et al., 2004). MDA-9/syntenin binds to internal or C-terminal sequences of important mammalian proteins through its two PDZ domains, and participates in multiple biological functions, including receptor clustering, protein trafficking, synaptic stabilization, activation of the transcription factor Sox4, syndecan recycling through endosomal compartments, and cell adhesion (Sarkar et al., 2008).
A noteworthy property of mda-9/syntenin is its ability to remodel the actin cytoskeleton in neurons (Hirbec et al., 2005) and multiple cancers, including melanoma (Koo et al., 2002; Helmke et al., 2004; Boukerche et al., 2005; Sulka et al., 2009). We previously documented that these changes driven by mda-9/syntenin expression initiate a signaling cascade resulting in FAK tyrosine phosphorylation and activation of the p38 MAPK pathway that subsequently leads to efficient activation of NF-κB in human melanoma cells and secretion of matrix metalloproteinase (MMP)-2 (Boukerche et al., 2007). In recent studies, we demonstrate that MDA-9/syntenin physically interacts with c-Src through its PDZ domains and this interaction correlates with an increase in the formation of an active FAK/c-Src signaling complex that ultimately promotes cell motility, and melanoma metastasis formation in vivo (Boukerche et al., 2008). These data strongly support a central role for the mda-9/syntenin/NF-κB pahway in sensing modifications in the state of the cytoskeleton and converting these transductional signals into changes in gene activity. However, despite these intriguing observations suggesting that NF-κB is a downstream mediator of mda-9/syntenin induction of melanoma cell invasion and migration, no mechanistic or functional data is currently available describing how or indeed even if MDA-9/syntenin/c-Src interactions are critical for NF-κB activation that promotes cancer progression (Boukerche et al., 2008).
The present studies uncover a novel mechanism regulating NF-κB activation involving functional cooperation between the tandem PDZ domains of MDA-9/syntenin and c-Src. Using a clinically representative human melanoma model, we: 1) show that the mda-9/syntenin/c-Src/NF-κB pathway is active in multiple cell types, including human melanomas and mouse embryo fibroblasts; 2) identify, through structure/function studies, the region of the PDZ domain required for NF-κB activation and determine that this activation requires the association of both PDZ domains of MDA-9/syntenin with c-Src, with PDZ-2 being the dominant module; and 3) demonstrate that the MDA-9/syntenin/c-Src complex functionally cooperates with the NF-κB transcription factor to promote anchorage-independent growth, motility and invasive potential of human melanoma cells, prominent contributors to cancer progression.
MDA-9/syntenin interacts with c-src and this interaction correlates with an increase in the formation of an active FAK/c-Src signaling complex and c-src activation in human melanoma cells that leads to enhanced tumor cell invasion and metastatic spread (Boukerche et al., 2008). mda-9/syntenin also initiates a signaling cascade resulting in the induction of NF-κB in human melanoma cells that ultimately promotes melanoma cell motility (Boukerche et al., 2007). In these contexts, we hypothesized that MDA-9/syntenin might activate the NF-κB pathway through its direct interaction with c-Src. To address this possibility, we initially determined the effect of PP2, a selective inhibitor of SFK members (Hanke et al., 1996), on activation of the NF-κB pathway. Infection of normal immortal melanocytes (FM516-SV) or poorly metastatic melanoma cells cells (M4Beu.), which express low-levels of mda-9/syntenin and have low-levels of constitutive NF-κB activity, with Ad.mda-9/S (100pfu/cell) resulted in nearly complete degradation of IκBα 2 h after plating cells on fibronectin compared with Ad.null-infected cells (Figures 1A, 1B). In contrast, after infection of FM516-SV or M4Beu. cells with Ad.mda-9/S (50pfu/cell), a dose-dependent decrease in IκBα degradation was observed with PP2 (5–10 µM), in comparison with the inactive congener PP3 (Figure 1A). Inhibition of IκBα expression by Ad.mda-9/S was also reversed by transfection with c-Src siRNA (Figures 1A, 1B). These results support a role of c-Src or other SFKs in mda-9/syntenin-induced NF-κB activation.
To confirm transcriptional activity of the NF-κB complexes, FM516-SV and M4Beu. melanoma cells were infected with Ad.null or Ad.mda-9/S and then transfected with either empty vector (pGL3Basic), 3kBmut-Luc, containing mutated NF-κB binding sites, or 3kB-Luc, containing three tandem NF-κB binding sites upstream of the luciferase gene. A 6- to 8-fold induction in relative luciferase activity, respectively, was observed in Ad.mda-9/S-infected FM516-SV or M4Beu. cells plated onto fibronectin compared with Ad.null-infected cells (Figures 1C, 1D). In contrast, when Ad.mda-9/S-infected FM516-SV or M4Beu. cells were treated with increasing concentration of PP2 (5–10 µM), a dose-dependent decrease in NF-κB transcriptional activity was seen compared to PP3 (Figures 1C, 1D). These results suggest that in this melanoma/melanocyte model NF-κB activation requires activation of the SFKs.
To further confirm an association between mda-9/syntenin-induced NF-κB activation and pp60c-src kinase, siRNAs were designed to specifically knockdown human c-Src (Boukerche et al., 2008) and the activation of NF-κB was analyzed by EMSA (Figure 2). As shown in Figure 2A and 2B, nuclear extracts prepared from FM515-SV and M4Beu. cells infected with Ad.mda-9/S (50pfu/cell) cells and plated on fibronectin contained significant levels of NF-κB consensus oligomer-binding activity compared to Ad.null-infected FM516-SV and M4Beu. cells. Incubating nuclear extracts with either anti-p50 or anti-p65 resulted in the appearance of two supershifted bands in M4Beu.- and FM516-SV-infected cells (Figure 2B; data not shown). In contrast, knockdown of endogenous c-Src in Ad.mda-9/S-infected FM516-SV- and M4Beu. cells (50pfu/cell) was accompanied by a dose-dependent decrease of NF-κB consensus oligomer-binding activity (up to ~80% and ~90% reduction, respectively) (Figures 2A, 2B) and NF-κB transcriptional activity (up to ~80% and ~85% reduction, respectively) (Figures 3A, 3B) when compared with untreated infected cells, or cells were treated with 50 nM of nontargeting siRNA complexes or siRNA targeting GAPDH. Similarily, treatment of metastatic melanoma variants, T1P26 and 7GP cells, and metastatic melanoma cell lines, SH-1, FO-1, MeWo and HO-1, with 10 and 50 nM siRNA complexes induced a dose-dependent decrease in NF-κB activity (up ~85% and ~90% reduction, respectively) (Figures 2C, 2D ; data not shown) and in transcriptional activity of the NF-κB-responsive promoter (up to ~85% and ~95% reduction, respectively) (Figures 3C, 3D ; data not shown) as compared with cells that were treated with nontargeting siRNA complexes or siRNA targeting GAPDH. In total, these results employing pharmacological and genetic approaches to block c-Src, support the hypothesis that in this melanocyte/melanoma model mda-9/syntenin-induced NF-κB activation requires SFK.
To verify that mda-9/syntenin-induced NF-κB activation was dependent on c-Src, we used mouse embryo fibroblasts (MEFs), denoted SYF −/− cells, lacking the three ubiquitous SFKs: Src, Yes, and Fyn (Klinghoffer et al., 1999). Plating SYF−/− cells on fibronectin failed to activate NF-κB (Figure 4). In contrast, littermate control MEFs expressing endogeneous c-Src (Src+/+,Yes−/−, Fyn−/−) or Src re-expression in SYF−/− cells (Src+/+) increased NF-κB activation by >3-fold compared to cells that were transfected with either empty pGL3Basic or 3kBmut-Luc. In addition, infection of SYF Src+/+ cells with Ad.mda-9/AS (50pfu/cell) resulted in a marked decrease in NF-κB activity (up to ~6-fold) compared with Ad.null-infected cells. Significantly, when SYF−/− cells were transiently co-transfected with mda-9/syntenin siRNA and wild-type c-Src, NF-κB transcriptional activity of NF-κB was not induced (Figure 4). These results support the conclusion that SYF cells have an intact mda-9/syntenin/Src/NF-κB pathway. Additionally, these data, provide further evidence that c-Src is necessary for mda-9/syntenin-induced NF-κB activation in SYF fibroblasts.
To investigate whether the PDZ domains of MDA-9/syntenin might differentially contribute to NF-κB activation, we engineered a series of eukaryotic expression vectors containing different MDA-9/syntenin PDZ domain deletion and point mutants (Figure 5A). All constructs produced expected sized products (Figure 5B). Transfection of MDA-9/syntenin or MDA-9 PDZ1+PDZ2 into M4Beu. cells significantly interacted with c-Src as compared to cells transfected with vector alone (Figure 5C) and increased NF-κB luciferase reporter activity (up to 6-fold) compared with either pGL3Basic or 3kBmut-Luc (Figure 5D). In contrast, MDA-9 ΔPDZ2, MDA-9PDZ1, or MDA-9ΔPDZ1+ΔPDZ2 did not interact with c-Src (Figure 5C) and lost NF-κB-inducibility (Figure 5D) indicating that both PDZ domains are crucial for mda-9/syntenin-mediated induction of NF-κB reporter activity.
To further address the binding specificity of MDA-9/syntenin PDZ domains, we generated a disruptive G128E (PDZ1*) and/or G212D (PDZ2*) mutation within the carboxylate-binding loop of each PDZ domain (Figure 5C). Retention of the interaction loops of PDZ1 and PDZ2 are critical for functional interaction of MDA-9/syntenin with its various transmembrane partners (Ponting et al., 1997; Koroll et al., 2001). Unlike the PDZ1* mutant, which was active, the PDZ2* and the double-mutant PDZ1*+PDZ2* significantly disrupted stable association of MDA-9/syntenin with c-Src (Figure 5C) and failed to activate the NF-κB-responsive reporter gene (~6-fold and ~7-fold reduction, respectively) (Figure 5D), thereby demonstrating that the second PDZ domain is required for MDA-9/syntenin–mediated induction of NF-κB reporter activity. In total, these findings employing PDZ domain mutants of full-length MDA-9/syntenin to block c-Src suggest that binding of MDA-9/syntenin to c-Src requires PDZ2, and that PDZ2 must be linked to PDZ1 to display NF-κB transcriptional activity in this melanocyte/melanoma model.
We next addressed the functional consequence of deletion and point mutations within the PDZ domains on the regulation of anchorage-independent growth and cell migration/invasion by melanoma cells, two prominent attributes of the metastatic phenotype of tumor cells. Overexpression of mda-9/syntenin or MDA-9 PDZ1+PDZ2 in FM516-SV or M4Beu. cells resulted in more and larger colonies growing in soft agar (Figure 6A) and in an enhanced invasive ability (Figure 6B), compared to untreated control or vector-transfected cells. In contrast, overexpression of MDA-9 ΔPDZ2, MDA-9ΔPDZ1, or MDA-9ΔPDZ1+ΔPDZ2 resulted in a significant decrease (~85–90% reduction) of the ability of FM516-SV and M4Beu. to form soft agar colonies (Fig. 6A) and invade the ECM (~85–90% reduction) vs. overexpression of wild-type MDA-9/syntenin protein (Figure 6B). Interestingly, compared to the PDZ1* mutant, the PDZ2* or the double-mutant PDZ1*+PDZ2* had profoundly inhibited soft agar colony formation (~90%–95% reduction) (Figure 6A) and migration/invasion ability of FM516-SV and M4Beu. cells vs. wild-type MDA-9/syntenin (Figure 6B). In total, these results suggest that binding of c-Src to MDA-9/syntenin-induced NF-κB activation requires the second MDA-9/syntenin PDZ2 domain to promote anchorage-independent growth of melanoma cells and to display a more invasive phenotype, and that the PDZ2 domain is functionally inactive if separated from PDZ1.
Because mda-9/syntenin induces an increase in the production of MMP-2 as well as activation of its proteolytic activity through NF-κB (Boukerche et al., 2007), we hypothesized that the PDZ domains of MDA-9/syntenin might regulate the activity and/or expression of MMP-2 through a c-Src/NF-κB-dependent pathway. As shown by reverse transcription-PCR (RT-PCR) and gelatin zymography, forced overexpression of MDA-9/syntenin or MDA-9 PDZ1+PDZ2 in M4Beu. cells caused a robust increase in the expression of MMP-2 mRNA (Figure 7A) and augmented both the latent (72-kDa) and the active (64-kDa) forms of MMP-2 gelatinase in conditioned medium (Figure 7B) vs. vector-transfected cells. MDA-9 ΔPDZ1, MDA-9 ΔPDZ2, or MDA-9 ΔPDZ1+ΔPDZ2 failed to enhance MMP2-mRNA levels (Figure 7A) or result in a significant increase in the levels of active MMP-2 and pro-MMP-2 expression (up to ~90–95% reduction of gelatinolytic activity) compared with wild type mda-9/syntenin-transfected M4Beu. cells (Figure 7B). Unlike the mutant PDZ1*, the mutant PDZ2* or the double-mutant PDZ1*+PDZ2* failed to enhance MMP2-mRNA expression (Figure 7A) and decreased significantly (~90%–95% reduction) the levels of active MMP-2 and pro-MMP-2 expression in M4Beu. cells (Figure 7B). Infection with an adenovirus expressing the mt32IκBα superrepressor (mt32IκBα–mt32) also decreased MMP-2 expression and activity (Figures 7A, 7B)
SFKs play important signaling roles both upstream and downstream of MAP kinases (Ikawa et al., 1997; Jalali et al., 1998; Volonte et al., 2001; Chen et al., 2001). Because mda-9/syntenin promotes tumor cell invasion/migration through activation of the p38 MAP kinase/NF-κB signaling pathway (Boukerche et al., 2007), we tested the ability of different mda-9/syntenin mutants to regulate the pathway that leads to up-regulation of MMP-2. The phosphorylated form of p38 was significantly inhibited by greater than ~75% to ~85% in M4Beu. melanoma cells overexpressing MDA-9 ΔPDZ2, MDA-9 ΔPDZ1, or MDA-9 ΔPDZ1+ΔPDZ2 compared with cells transfected with wild type MDA-9/syntenin or MDA-9 PDZ1+PDZ2 (Figure 7C). As anticipated, transfection of M4Beu. cells with either a mutant PDZ2* or a double-mutant PDZ1*+PDZ2* significantly decreased the activation of p38 and MMP-2 expression compared with PDZ1* mutant-transfected cells (Figures 7C, 7D). Consistent with these results, blocking p38 signaling using SB203580 or employing an Ad.p38DN mutant construct had no effect on the activation state of c-Src in metastatic melanoma variants 7GP and T1P26, whereas it markedly down-regulated NF-κB activation (Figures 7E, 7F; data not shown). In contrast, siRNA knockdown of c-Src expression significantly inhibited p38 activation (Figure 7G), and as shown in this study, NF-κB activation. In total, these data suggest that binding of MDA-9/syntenin to the PDZ1 and PDZ2 domains to c-Src are required for pro-MMP-2 activation and that p38 acts as a downstream target of c-Src in the signaling pathway that leads to NF-κB activation, thereby promoting tumor cell migration/invasion.
We presently document that MDA-9/syntenin binding to c-Src is a key step in activation of the NF-κB pathway and its downstream target genes leading to cell migration and invasion. (A) Pharmacological inhibition of SRKs, silencing of endogeneous c-Src by siRNA, or genetic ablation of SRKs inhibited mda-9/syntenin-induced activation of NF-κB in human melanoma cells. (B) Deletion of either one of the two PDZ domains of MDA-9/syntenin strongly reduced the interaction of MDA-9/syntenin with c-Src and the transcriptional activation of NF-κB in melanoma cells. (C) c-Src interaction with MDA-9/syntenin induced NF-κB activation and subsequent migration/invasion and anchorage-independent growth of poorly metastatic melanoma cells. This interaction was significantly inhibited following transfection with mda-9/syntenin encoding either PDZ1- and/or PDZ2-deleted regions. These data provide the first report that c-Src is required for mda-9/syntenin-mediated induction of NF-κB. Consistent with previous reports (Grootjans et al., 2000; Geijsen et al., 2001; Koroll et al., 2001; Jannatipour et al., 2001), we found that both independent PDZ domains and the tandem PDZ domains of MDA-9/syntenin through interactions with c-Src directly mediate NF-κB activation and play a crucial mechanistic role in mediating augmentation of invasive and tumorigenic potential by melanoma cells.
Although our data show that activation of the transcription factor NF-κB requires the tandem PDZ domains of MDA-9/syntenin, mutation of one of the key contact residues within each PDZ domain for its transmembrane partners (Ponting et al., 1997; Koroll et al., 2001) documents that the functional integrity of the carboxylate-binding loop of PDZ2, but not of PDZ1, is essential for c-Src binding and activation of the transcription factor NF-κB. These findings raise obvious questions as to how PDZ1 contributes to the interaction of MDA-9/syntenin with c-Src, and how it then regulates NF-κB activation and subsequent MMP-2 activation, thereby promoting tumor migration and invasion? Increasing experimental evidence indicates that PDZ domains in multi-PDZ domain-containing proteins are grouped into functional units and that tandemly arranged PDZ repeats are often necessary to mediate specific interactions with its binding partners (Grootjans et al., 2000; Sarkar et al., 2004; Meerschaert et al., 2007). Current structural data indicate that PDZ domains in these functional units mutually chaperone each other, enabling the tandem PDZ domains to interact with its target (Zhang et al., 2001). Indeed, it has been shown that PDZ4 and PDZ5 domains in glutamate receptor interacting protein (GRIP) mutually chaperone each other, enabling tandem PDZ domains to interact with GluR2 (Dong et al., 1997; Zhang et al., 2001). The similar structural features of the paired MDA-9/syntenin PDZ domains (Kang et al., 2003) suggest that the PDZ1 domain of MDA-9/syntenin may be essential for proper folding of PDZ2. Indeed, the two PDZ domains of MDA-9/syntenin are structurally associated and undergo denaturation in a highly cooperative manner (Kang et al., 2003). Additionally, structural integrity of MDA-9/syntenin is required for it’s self-association for promoting PDZ domain-mediated protein interactions (Koroll et al., 2001). Accordingly, it is possible that following binding of c-Src to the MDA-9/syntenin PDZ2 domain, PDZ1 promotes the proper folding of PDZ2 that assemble MDA-9/syntenin into a multimeric complex resulting in a more stable functional unit (Figure 8). In support of this conclusion, heteronuclear NMR and single crystal X-ray diffraction indicate that cooperative binding of MDA-9/syntenin to syndecan results in improved binding affinity relative to single PDZ modules of MDA-9/syntenin (Bass et al., 2002).
Our previous observations of enhanced anchorage-independent growth and motility of melanoma induced by mda-9/syntenin suggested a role for FAK/p38 MAPK/NF-κB signaling pathways in the regulation of MMP-2 activity, that in turn lead to migration and extracellular matrix (ECM) invasion by melanoma cells (Boukerche et al., 2005; 2007). We found that inhibition of PDZ domain-mediated protein interactions with c-Src blocked p38 MAPK, NF-κB, and MMP-2 activation and that inhibiting p38 MAPK had little effect on the activation state of c-Src in melanoma. These results strongly suggest that MDA-9/syntenin bound to c-Src is upstream of p38 MAPK and that these two different signaling molecules functionally cooperate with FAK-induced activation of the NF-κB/MMP-2 pathway to promote migration/invasion of melanoma cells (Boukerche et al., 2005; 2007). The observations that c-Src can activate p38 MAPK (Zhou et al., 2004; Mikami et al., 2005; Galliher-Beckley et al., 2008) and stimulate NF-κB (Ten et al., 1999; Petro et al., 2000) in other cellular contexts lend further support for a critical role of the c-Src/p38 MAPK signaling pathways as mediators of MDA-9/syntenin-induced NF-κB activation in melanoma.
How might MDA-9/syntenin acting through c-Src mediate NF-κB activation that leads to MMP-2 activation? NF-κB is maintained in an inactive form with IκB proteins. Following induction, the activated IKK complex mediates the phosphorylation and degradation of IκBα, and the p50–p65 NF-κB translocates into the nucleus where it binds to consensus NF-κB sequences in the promoter of diverse target genes, thereby augmenting their transcription (Orlowski et al., 2002). MDA-9/syntenin-induced NF-κB activation occurs following complex formation with c-Src at the focal contacts through its PDZ domains (Boukerche et al., 2008). c-Src can lead to NF-κB activation through IKKβ and/or IκBα tyrosine phosphorylation in several cell types (Storz and Toker, 2003; Liu et al., 2005; Funakoshi-Tago et al., 2005; Lee et al., 2007) suggesting that recruitment of MDA-9/syntenin to focal contact sites is a critical step that allows c-Src bound to MDA-9/syntenin to activate the NF-κB pathway in our melanoma model, which ultimately results in MMP-2 production and melanoma cell migration and invasion. Accordingly, we observed that pharmacological inhibition of SFKs with PP2 caused IκBα degradation that parallels phosphorylation of IKKα/β in melanoma cells expressing mda-9/syntenin (Figure 1; data not shown). Consequently, MDA-9/syntenin might assemble large Src-FAK complexes including IKKβ and/or IkBα that greatly enhances NF-κB activity. Future studies are required to determine the nature of the downstream kinases that link MDA-9/syntenin to NF-κB activation.
On the basis of our observations, we suggest a model in which recruitement of MDA-9/syntenin at focal adhesions and interaction of its PDZ domains with c-Src through a cooperative binding mechanism may assemble c-Src/FAK signaling complexes at high density at the plasma membrane that positively regulate NF-κB to promote cell motility and metastasis (Marsuo et al., 2006) (Fig. 8). Melanoma is a complex genetic disease, the management of which will require an in-depth understanding of the biology underlying its initiation and progression. Blocking mda-9/syntenin (Boukerche et al., 2005; 2007) or interference with NF-κB regulated genes such as MMP-2 (Chu et al., 2007), the VEGF pathway (Perez et al., 2009), or more importantly inhibition of c-Src (Warmuth et al., 2003) or NF-κB itself (Sarkar et al., 2008), has been shown to inhibit tumor growth and neovascularization of cancer cells in preclinical studies and clinical trials. Considering the critical role that the MDA-9/c-Src complex plays in the activation of the NF-κB pathway that leads to the coordinate expression of several genes involved in invasion and angiogenesis (Boukerche et al., 2008; Sarkar et al., 2008), our studies suggest that targeting the PDZ domains of MDA-9/syntenin with peptides or small molecules could provide a means of preventing the spread of cancer in the clinical setting.
The following reagents were obtained from the indicated providers: anti-c-Src and anti-IκBα (Santa Cruz Biotechnology, CA), anti-HA (Covance Research Products, Denver, PA), anti-MDA-9/syntenin polyclonal antibody (Alpha-Diagnostic International, San Antonio, TX), anti-p38 and anti-phospho-p38 (Cell Signaling, Beverly, MA), SB103580, PP2 and PP3 (Sigma-Aldrich, La Jolla, CA), Luciferase Reporter Gene (Promega Corp., Madison, WI), Fugene 6 (Roche Applied Bioscience). FM516-SV are normal human melanocytes immortalized by the SV40 T-antigen gene. The highly metastatic 7GP and T1P26 human melanoma cell line variants were derived from a poorly metastatic M4Beu. melanoma cell line (Baril et al., 2002; Boukerche et al., 2000; 2004). We also used the following metastatic human melanoma cell lines: SH-1, FO-1, MeWo and HO-1 (Boukerche et al., 2005). SYF cells and c-Src reexpressing (Src+/+) mouse embryo fibroblast cells were purchased from the American Type Culture Collection.
Construction and characterization of Ad.mda-9/S (Ad expressing mda-9/syntenin), Ad.mda-9/AS (Ad expressing an antisense construct of mda-9/syntenin) and a dominant-negative kinase-deficient mutant p38 mitogen-activated protein kinase (MAPK) were performed as described (Boukerche et al., 2005). Cells (2 × 105) were infected with 25 to 100 plaque-forming units/cell of the indicated type 5 Ad for 2 h in DMEM. Forty-eight to 96 h post-transduction, cells were serum-starved and plated on fibronectin as described (Boukerche et al., 2005; 2007).
The N-terminal HA-tagged mda-9/syntenin expression plasmid in the backbone of pMT2-HA vector and the plasmid encoding PDZ-1 domain plus N-terminal, and N-terminal of MDA-9/syntenin, respectively was kindly provided by P.J. Coffer (University Medical Center, Utrecht, The Netherlands) (Geijsen et al., 2001). The constructs coding for HA-tagged MDA-9/syntenin PDZ1-PDZ2 + C-terminal segment was obtained by PCR with: sense 5’-ATGAATTCGCAGAAATTAAGCAAGGGATTCGTGAAGT-3’; antisense 5’-ATCTCGAGTCCATGGTGCCTCGAGTTTTAAACCTC-3’. The HA-MDA-9/syntenin PDZ2 + C-terminal segment construct was generated by PCR with: sense 5’-ATGAATTCTTACCATGACCATTCGGGATCCGCCCTT-3’; antisense 5’-ATCTCGAGTCCATGGTGCCTCGAGTTTTAAACCTC-3’. The products were cloned into EcoRI/XhoI-restricted pMT2-HA vector. The N-terminal HA-tagged mda-9/syntenin expression plasmid in the backbone of pCMV-HA (Clontech) was used as template to generate different mutant constructs by PCR. The amino acid substitutions G128E and G212D within the PDZ1 and PDZ2 of MDA-9/syntenin, respectively, were generated by QuickChange® site-directed mutagenesis: pGATCAAGATGGAAAAATTGAGCTCAGACTGAAGTCAG and pCTGACTTCAGTCTGAGCTCAATTTTTCCATCTTGATC or pGGACAGCAGTGGACATGTTGACTTTATCTTTAAATGGA and pTCCACTTTTAAAGATAAAGTCAACATGTCCACTGCTGTCC. The G128E mutant was used as template to perform the G212D site-directed mutagenesis. pSGT-wt c-Src was a generous gift from Serge Roche (CNRS, Montpellier, France). For luciferase assays, cells were infected with the different Ad constructs at a m.o.i. of 50 pfu/cell. Twelve h later, cells were transfected with a NF-κB luciferase reporter plasmid with Fugene 6 Transfection Reagent (Boukerche et al., 2007). Transient cotransfection were conducted either with the vector alone, wt-c-src, mda-9/syntenin, or its different mutants along with the NF-κB–responsive luciferase reporter construct. Forty-eight h later, cells were plated onto fibronectin for 1 h. For inhibition experiments, the cells were pretreated with different inhibitors for 20 min before plating on fibronectin. Data represent the average of triplicates ± S.D.
Cells were infected with the indicated Ad at a m.o.i. of 50 pfu/cell. Twelve h later, cells were cotransfected with either an irrelevant RNA duplex or a pool of two c-Src-targeted siRNA sequences (5’-AACAAGAGCAAGCCCAAGGAT-3’ (52–71-bp) and 5’-AAGCACUACAAGAUCCGCAAG-3’ (607–628-bp) along with a NF-κB-responsive luciferase reporter construct using Fugene 6 (Boukerche et al., 2007; 2008). For transfection with mda-9/syntenin siRNA, a pool of two effective sequences was chosen: 5’-ATGGTGGCTCCTGTAACTGGT-3’ and 5’-GCUAUAGCAUAGCUGCUUATT-3’. Luciferase assays were performed 48 h after transfection. Data represent the average of triplicates ± S.D. A silencer negative control siRNA (Ambion) was included in the study.
Cells infected with the indicated Ad, or transfected with either an irrelevant RNA duplex or c-Src specific siRNAs, were washed in cold PBS. Cytoplasm and nuclear extracts were then prepared and EMSA using nuclear extracts were done as described (Boukerche et al., 2007).
Two micrograms of total RNA isolated with the Qiagen RNeasy mini kit were used for reverse transcription-PCR using Superscript II reverse transcriptase (Invitrogen). MMP-2 sense, 5’-GTGCTGAAGGACACACTAAAGAAGA-3’; MMP-2 antisense, 5’-TTGCCATCCTTCTCAAAGTTGTAGG-3’; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense, 5’-ATGGGGAAGGTGAAGGTCGGAGTC-3’; GAPDH antisense, 5’-GCTGATGATCTTGAGGCTGTTGTC-3’.
Cells transfected either with the indicated plasmids or infected with the indicated Ad were lysed in RIPA buffer. Equal amounts of proteins were resolved in SDS/PAGE, transferred, and evaluated for IκBα and p38 MAPK phosphorylation (Boukerche et al., 2007). For coimmunoprecipitations, cells were lysed in a modified radioimmunoprecipitation assay buffer [50 mmol/L HEPES (pH 7.4), 0.15 mol/L NaCl, 1% Triton X-100, 1 mmol/L MgCl2, and 1 mmol/L CaCl2] containing protease inhibitor cocktail, 25 mmol/L NaF, 2 mmol/L Na3V04, and 20 mmol/L Na4P2O7, and equivalent amounts of cell lysates were incubated for 2 h at 4°C with antibodies to c-Src coupled to protein G-Sepharose (Boukerche et al., 2008). The eluted precipitates were resolved by SDS/PAGE, transferred and probed with anti-HA (1:1,000; mouse monoclonal).
Briefly, after cells were transfected with the indicated plasmids, the medium was replaced with serum-free minimum essential medium. Sixteen h later, the conditioned medium was collected and analyzed by zymography in gelatin-containing gels (Boukerche et al., 2007).
Cells (2 × 105) were transfected either with the vector alone, or with mda-9/syntenin or its different mutants using standard Fugene 6 Transfection Reagent. Forty-eight h after transfection, colony formation in soft agar and tumor cell migration/invasion assays were performed as described (Fidler et al., 1991; Boukerche et al., 2005).
This work was supported by National Institutes of Health, National Cancer Institute grants R01 CA035675 and CA097318, the Samuel Waxman Cancer Research Foundation (SWCRF), the National Foundation for Cancer Research (NFCR) (PBF); the Goldhirsh Foundation and the Dana Foundation (DS); and the Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer grant 1019 (HB). DS is the Harrison Endowed Scholar in Cancer Research and PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center. PBF is a SWCRF Investigator.
Conflict of interest
The authors declare no conflict of interest.
*This work was supported by National Institutes of Health, National Cancer Institute grants R01 CA35675 and CA097318, the Samuel Waxman Cancer Research Foundation, the National Foundation for Cancer Research (PBF) ; the Goldhirsh Foundation and the Dana Foundation (DS); and the Ligue nationale contre le Cancer and Association pour la Recherche sur le Cancer grant 1019 (HB). DS is the Harrison Endowed Scholar in Cancer Research and PBF holds the Thelma Newmeyer Corman Chair in Cancer Research at the VCU Massey Cancer Center and a SWCRF Investigator.